UCB SA (UCBJF)
| Market Cap | 49.18B +21.7% |
| Revenue (ttm) | 9.74B +24.5% |
| Net Income | 2.51B +64.7% |
| EPS | 12.93 +64.9% |
| Shares Out | n/a |
| PE Ratio | 19.62 |
| Forward PE | 17.50 |
| Dividend | 1.71 (0.63%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 1 |
| Open | 269.84 |
| Previous Close | 258.48 |
| Day's Range | 269.84 - 269.84 |
| 52-Week Range | 211.48 - 345.39 |
| Beta | 0.18 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for... [Read more]
Financial Performance
In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.
Financial numbers in EUR Financial StatementsNews
UCB upgraded to Hold from Underperform at Jefferies
Jefferies upgraded UCB (UCBJF) to Hold from Underperform with a price target of EUR 220, up from EUR 212. The firm says its sell thesis has played out while UCB’s…
UCB SA Earnings Call Transcript: H1 2026
First-half 2026 saw net sales rise 23% to EUR 4.1 billion, driven by five growth products now over half of revenue. Upgraded guidance reflects strong BIMZELX momentum, new peak sales target above EUR 7 billion, and robust pipeline expansion through acquisitions and clinical advances.
UCB SA Earnings release: H1 2026
UCB SA released its H1 2026 earnings on July 30, 2026, summarizing the period's financial results.
UCB SA Quarterly report: H1 2026
UCB SA has published its H1 2026 quarterly earnings report on July 30, 2026.
UCB SA Slides: H1 2026
UCB SA has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 30, 2026.
UCB shares fall despite guidance upgrade as investors question earnings quality
Belgian biopharmaceutical group UCB raised its 2026 earnings guidance on Thursday, but its shares fell more than 8% as investors focused on weaker-than-expected sales of flagship drug Bimzelx and qu...
UCB Maintained by DA Davidson -- Price Target Stays at $40
UCB Maintained by DA Davidson -- Price Target Stays at $40
UCB (UCB) Q2 2026 Earnings Call Transcript
Net interest margin expanded for sixth straight quarter as loan growth accelerated.
United Community Banks Reports Weak Q2 2026 as EPS Misses by 13.4%
Earnings Miss. United Community Banks, Inc. (UCB) reported Q2 2026 operating earnings of $0.71 per share, falling short of the $0.82 consensus estimate by 1... The post United Community Banks Reports ...
United Community Banks (UCB) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for United Community Banks (UCB) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metr...
United Community Banks Inc. Bottom Line Advances In Q2
(RTTNews) - United Community Banks Inc. (UCB) revealed a profit for its second quarter that Increased, from last year
United Community Banks (UCB) Q2 2026 Preview: EPS Est. $0.82, Reports July 21
Wall Street expects United Community Banks to report earnings of $0.82 per share on revenue of $280.3 million when the regional bank releases its Q2 2026 res... The post United Community Banks (UCB) Q...
UCB price target raised to EUR 305 from EUR 290 at Berenberg
Berenberg analyst Kerry Holford raised the firm’s price target on UCB (UCBJF) to EUR 305 from EUR 290 and keeps a Buy rating on the shares.
UCB downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Charles Pitman-King downgraded UCB (UCBJF) to Equal Weight from Overweight with a price target of EUR 300, down from EUR 310. The firm cites the company’s growth investments…
UCB SA Transcript: Investor update
BE BOLD demonstrated bimekizumab's statistically significant superiority over risankizumab in joint outcomes for psoriatic arthritis, with sustained efficacy and a safety profile consistent with prior studies. The results are expected to influence clinical guidelines, prescribing practices, and payer dynamics, supporting bimekizumab's positioning as a first-line therapy.
UCB SA Slides: Investor update
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
Cullinan jumps after UCB acquires Candid Therapeutics
Shares of Cullinan Therapeutics (CGEM) are moving higher after UCB (UCBJF) announced an agreement to acquire privately held Candid Therapeutics. Cizutamig, Candid’s lead investigational asset, is “pos...
UCB to Buy Candid Therapeutics for Up to $2.2 Billion
The deal seeks to bolster the company's pipeline of experimental treatments for autoimmune and inflammatory diseases.
Belgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billion
Belgian biopharmaceuticals company UCB has agreed to buy privately-held Candid Therapeutics in a deal worth up to $2.2 billion, the companies said on Sunday.
UCB SA Slides: Acquisition presentation
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on May 3, 2026.
UCB to acquire Neurona Therapeutics
UCB (UCBJF) announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. Neurona Th...
UCB downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Sarita Kapila downgraded UCB (UCBJF) to Equal Weight from Overweight with an unchanged price target of EUR 260. The firm sees a balanced risk/reward at current share…
Belgium's UCB in autoimmune drug deal with Antengene
Belgian drugmaker UCB has entered into an agreement to licence Antengene's experimental autoimmune disease therapy ATG-201 and associated technology, paying $60 million up front and over $1.1 billio...
UCB SA Earnings Call Transcript: H2 2025
Net sales surged 35% year-over-year, led by Bimzelx and four other growth drivers, with strong pipeline progress and a robust financial position. 2026 guidance anticipates continued high single to low double-digit revenue growth and margin expansion, supported by strategic investments and portfolio differentiation.
UCB SA Annual report: H2 2025
UCB SA has published its H2 2025 annual report on February 26, 2026.